环磷酰胺联合他莫昔芬治疗卵巢恶性肿瘤的效果及其安全性分析  

The Analysis of Efficacy and Safety of Cyclophosphamide Combined with Tamoxifen in the Treatment of Patients with Ovarian Malignant Tumors

作　　者：李慧荣 孔艳 辛刚[2] 白吉丽 许瑞 董延磊[4] 李丽丽 白雪 朱琳[2] LI Huirong;KONG Yan;XIN Gang;BAI Jili;XU Rui;DONG Yanlei;LI Lili;BAI Xue;ZHU Lin(Department of Obstetrics and Gynecology, Shandong Provincial Third Hospital, Jinan, Shandong, 250031, China;De-partment of Obstetrics;Department of Gynaecology, the Second Hospital of Shandong University, Jinan, Shandong, 250000, China;Department of Obstetrics and Gynecology, the Third People’ s Hospital of Lixia District in Jinan City, Jinan, Shandong, 250010, China)

机构地区：[1]山东省立第三医院妇产科,山东济南250031 [2]山东大学第二医院产科,山东济南250000 [3]济南市历下区第三人民医院妇产科,山东济南250010 [4]山东大学第二医院妇科,山东济南250000

出　　处：《肿瘤药学》2018年第2期188-191,共4页Anti-Tumor Pharmacy

基　　金：国家自然基金资助项目(39730380)

摘　　要：目的探讨环磷酰胺联合他莫昔芬治疗卵巢恶性肿瘤的效果及其安全性。方法选取2012年1月~2017年1月我院收治的卵巢恶性肿瘤患者60例作为研究对象,根据治疗方法不同分成两组,对照组给予环磷酰胺治疗,研究组患者给予环磷酰胺联合他莫昔芬治疗。对比两组患者的治疗有效率、复发率及生存率、毒副反应和生活质量。结果治疗后研究组治疗有效率显著高于对照组(P<0.05);研究组术后复发率显著低于对照组且生存率显著高于对照组(P<0.05);治疗后研究组患者的毒副反应显著轻于对照组(P<0.05);治疗后研究组生活质量显著优于对照组(P<0.05)。结论采用环磷酰胺联合他莫昔芬治疗卵巢恶性肿瘤患者,可显著提高治疗有效率,降低术后复发率,有效改善患者生活质量,值得临床进一步推广应用。Objective To investigate the efficacy and safety of cyclophosphamide combined with tamoxifen in the treatment of patients with ovarian malignant tumors. Methods Between January 2012 and January 2017, 60 ovarian cancer patients were selected from our hospi-tal as the research objects, and they were divided into two groups according to the different treatment methods. The control group was treated with cyclophosphamide treatment, and the experimental group was given cyclophosphamide combined with tamoxifen treatment. The treat-ment efficacy, recurrence rate and survival rate, toxicity and quality of life of patients were compared between the two groups. Results After treatment, the effective rate of the experimental group was significantly higher than that of the control group （P〈0.05）. The recurrence rate of the experimental group according to the follow-up record was significantly lower than that of the control group （P〈0.05）. The survival rate was significantly higher in the experimental group than in the control group （P〈0.05）. The incidence of adverse reactions of patients after treatment was significantly lower in the experimental group than in the control group （P〈 0.05）. After treatment, the quality of life of pa-tients was significantly better in the experimental group than in the control group （P〈0.05）. Conclusion Cyclophosphamide combined with tamoxifen in the treatment of ovarian cancer patients can significantly improve the efficiency of treatment, reduce postoperative recurrence rate, and improve the life quality of patients effectively. It is worthy of further promotion and application in clinic.

关 键 词：卵巢恶性肿瘤 环磷酰胺 他莫昔芬 安全性分析 生活质量 

分 类 号：R737.31[医药卫生—肿瘤]